CD168 + macrophages promote hepatocellular carcinoma tumor stemness and progression through TOP2A /β-catenin/ YAP1 axis
iScience, ISSN: 2589-0042, Vol: 26, Issue: 6, Page: 106862
2023
- 9Citations
- 7Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef9
- Captures7
- Readers7
- Mentions1
- News Mentions1
- News1
Most Recent News
Shanxi Medical University Details Findings in Liver Cancer [Cd168(+) Macrophages Promote Hepatocellular Carcinoma Tumor Stemness and Progression Through Top2a/beta-catenin/yap1 Axis]
2023 AUG 17 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Investigators publish new report on Oncology - Liver Cancer. According
Article Description
Liver cancer stem-like cells (LCSCs) are the main cause of heterogeneity and poor prognosis in hepatocellular carcinoma (HCC). In this study, we aimed to explore the origin of LCSCs and the role of the TOP2A/β-catenin/YAP1 axis in tumor stemness and progression. Using single-cell RNA-seq analysis, we identified TOP2A + CENPF + LCSCs, which were mainly regulated by CD168 + M2-like macrophages. Furthermore, spatial location analysis and fluorescent staining confirmed that LCSCs were enriched at tumor margins, constituting the spatial heterogeneity of HCC. Mechanistically, TOP2A competitively binds to β-catenin, leading to disassociation of β-catenin from YAP1, promoting HCC stemness and overgrowth. Our study provides valuable insights into the spatial transcriptome heterogeneity of the HCC microenvironment and the critical role of TOP2A/β-catenin/YAP1 axis in HCC stemness and progression.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2589004223009392; http://dx.doi.org/10.1016/j.isci.2023.106862; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85160321401&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37275516; https://linkinghub.elsevier.com/retrieve/pii/S2589004223009392; https://dx.doi.org/10.1016/j.isci.2023.106862
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know